The Ongoing Shortage of PSMA-targeted Radionuclide Therapy, Lu177 vipivotide tetraxetan (Pluvicto) and Its Devastating Impact on Prostate Cancer Care: Insights from a Medical Oncologist and Hematologist at UPMC Hillman Cancer Center.
The world of cancer treatment is constantly evolving, and new breakthroughs are often met with excitement, hope, and the promise of better outcomes for patients. One such breakthrough is the PSMA-targeted radionuclide therapy, Lu177 vipivotide tetraxetan, also known as Pluvicto. This promising treatment option has shown great potential for patients with metastatic castration-resistant prostate cancer, … Read more